- Home
- CMND vs ONCO Comparison
CMND vs ONCO Comparison
Compare CMND & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMND | ONCO |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CMND | ONCO |
|---|---|---|
| Price | $1.12 | $0.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 107.0K | ★ 506.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,524,116.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4217.31 |
| 52 Week Low | $0.07 | $0.05 |
| 52 Week High | $3.25 | $7.65 |
Technical Indicators
Market Signals| Indicator | CMND | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 30.30 |
| Support Level | $0.93 | $0.07 |
| Resistance Level | $1.27 | $1.87 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 14.29 | 0.82 |
Price Performance
Historical ComparisonAbout CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.